stockrowCelldex Therapeutics, Inc. (CLDX) vs Recursion Pharmaceuticals, Inc. (RXRX)
- Celldex Therapeutics, Inc. CLDX 29.76 +5.27%
- Recursion Pharmaceuticals, Inc. RXRX 3.58 +2.29%
Celldex Therapeutics, Inc. and Recursion Pharmaceuticals, Inc. are both Biotechnology companies. Celldex Therapeutics, Inc. and Recursion Pharmaceuticals, Inc. are of similar size ($2.2B and $2.2B). Recursion Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 56.2% against −88.3%. Recursion Pharmaceuticals, Inc. has the higher net margin (−697.1% vs −33,883.8%) and the lower return on invested capital (−88.5% vs 0.00%). Across the 18 metrics below, Recursion Pharmaceuticals, Inc. leads on 12 and Celldex Therapeutics, Inc. on 6.
Valuation
Profitability
| Metric | CLDX | RXRX | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 29.21% | 65.16% |
| Operating margin | (36,733.82%) | (725.44%) | 0.00% |
| Net margin | (33,883.77%) | (697.13%) | 0.00% |
| Free cash flow margin | (27,294.81%) | (460.89%) | 0.00% |
| Return on equity | (43.88%) | (48.72%) | (50.12%) |
| Return on assets | (40.76%) | (36.29%) | (45.60%) |
| Return on invested capital | 0.00% | (88.54%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack